[go: up one dir, main page]

MXPA03001982A - Amino-aza-cicloalcanos sustituidos utiles contra la malaria. - Google Patents

Amino-aza-cicloalcanos sustituidos utiles contra la malaria.

Info

Publication number
MXPA03001982A
MXPA03001982A MXPA03001982A MXPA03001982A MXPA03001982A MX PA03001982 A MXPA03001982 A MX PA03001982A MX PA03001982 A MXPA03001982 A MX PA03001982A MX PA03001982 A MXPA03001982 A MX PA03001982A MX PA03001982 A MXPA03001982 A MX PA03001982A
Authority
MX
Mexico
Prior art keywords
aza
substituted amino
useful against
against malaria
compounds
Prior art date
Application number
MXPA03001982A
Other languages
English (en)
Inventor
Thomas Weller
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MXPA03001982A publication Critical patent/MXPA03001982A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La invencion se refiere a compuestos nuevos que son derivados de amino-aza-cicloalcanos sustituidos de la formula general I. La invencion se refiere tambien a aspectos relacionados que incluyen procedimientos para la preparacion de los compuestos, composiciones farmaceuticas que contienen uno o mas compuestos de la formula general I y especialmente a su uso como inhibidores de la proteasa plasmepsina II de plasmodium falciparum o proteasas asparticas relacionadas.
MXPA03001982A 2000-09-25 2001-09-06 Amino-aza-cicloalcanos sustituidos utiles contra la malaria. MXPA03001982A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0009328 2000-09-25
PCT/EP2001/010272 WO2002024649A1 (en) 2000-09-25 2001-09-06 Substituted amino-aza-cycloalkanes useful against malaria

Publications (1)

Publication Number Publication Date
MXPA03001982A true MXPA03001982A (es) 2004-05-14

Family

ID=8164106

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001982A MXPA03001982A (es) 2000-09-25 2001-09-06 Amino-aza-cicloalcanos sustituidos utiles contra la malaria.

Country Status (13)

Country Link
US (1) US20040102431A1 (es)
JP (1) JP2004509866A (es)
KR (1) KR20030029978A (es)
CN (1) CN1458923A (es)
AU (1) AU2001291830A1 (es)
BR (1) BR0113989A (es)
CA (1) CA2423315A1 (es)
HU (1) HUP0303360A2 (es)
IL (1) IL154363A0 (es)
MX (1) MXPA03001982A (es)
NO (1) NO20031331L (es)
WO (1) WO2002024649A1 (es)
ZA (1) ZA200302290B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002304733A1 (en) * 2001-04-17 2002-10-28 Actelion Pharmaceuticals Ltd. Amino-aza-cyclohexanes for the treatment of malaria
JP2005504042A (ja) * 2001-08-03 2005-02-10 シェーリング　コーポレイション γセクレターゼインヒビターのようなスルホンアミド誘導体
EP1466904A4 (en) * 2001-12-28 2005-12-14 Takeda Pharmaceutical BIARYL CONNECTION AND ITS USE
TW200409637A (en) 2002-06-26 2004-06-16 Glaxo Group Ltd Compounds
WO2004009549A2 (en) * 2002-07-18 2004-01-29 Actelion Pharmaceuticals Ltd Piperidines useful for the treatment of central nervous system disorders
DE60327106D1 (de) * 2002-12-20 2009-05-20 Chemocentryx Inc Inhibitoren der bindungder chemokine i-tac bzw. sdf-1 an den ccxckr2-rezeptor
CN1816524B (zh) 2003-01-16 2012-06-27 阿卡蒂亚药品公司 用于神经退行性疾病的治疗的选择性五羟色胺2a/2c受体反向激动剂
AU2004273773B2 (en) * 2003-02-21 2008-01-24 Jarrow Formulas, Inc. Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors
AU2004247487B2 (en) 2003-06-17 2010-05-20 Pfizer Inc. N-pyrrolidin-3-YL-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
WO2005019176A1 (en) * 2003-08-25 2005-03-03 Actelion Pharmaceuticals Ltd Substituted amino-aza-cyclohexanes
WO2005058822A1 (en) * 2003-12-17 2005-06-30 Actelion Pharmaceuticals Ltd Substituted amino-cycloalkanes
ATE471320T1 (de) 2004-02-27 2010-07-15 Lilly Co Eli 4-aminopiperidinderivate als inhibitoren der monoamin-aufnahme
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
EP1789404B1 (en) 2004-06-30 2010-03-24 Schering Corporation Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors
WO2006038989A1 (en) * 2004-09-29 2006-04-13 Chemocentryx, Inc. Substituted arylamides
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
CA2587888A1 (en) * 2004-11-25 2006-06-01 Actelion Pharmaceuticals Ltd Novel 4-aminopiperidine derivatives as plasmepsin ii inhibitors
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
US20090053329A1 (en) 2007-03-19 2009-02-26 Acadia Pharmaceuticals, Inc. Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2009106599A2 (en) * 2008-02-29 2009-09-03 Novartis Ag Substituted piperidines as therapeutic compounds
WO2011060271A1 (en) * 2009-11-12 2011-05-19 The Trustees Of The University Of Pennsylvania Screening for inhibitors of p. falciparum using luciferase based high throughput screening assay
KR101035503B1 (ko) * 2010-03-19 2011-05-20 변태희 맞춤형 어버트먼트 가공용 자재
WO2013077886A2 (en) 2010-12-01 2013-05-30 The Methodist Hospital System Protease degradable polypeptides and uses thereof
US9439976B2 (en) 2013-02-13 2016-09-13 The Methodist Hospital System Compositions and methods for using cathepsin E cleavable substrates
EP2970217B1 (en) 2013-03-15 2017-08-09 Idorsia Pharmaceuticals Ltd Novel acrylamide derivatives as antimalarial agents
JP2018521021A (ja) 2015-06-11 2018-08-02 バジリア・ファルマスーチカ・インターナショナル・アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ａｇ 排出ポンプ阻害剤及びその治療的使用
SI3325444T1 (sl) 2015-07-20 2021-11-30 Acadia Pharmaceuticals Inc. Postopki za pripravo N-(4-fluorobenzil)-N-(1-metilpiperidin-4-il)-N'- (4-(2-metilpropiloksi)fenilmetil)karbamida in njegove tartratne soli in polimorfne oblike C
KR20180052678A (ko) 2015-09-16 2018-05-18 메타크린, 인크. 파네소이드 x 수용체 아고니스트 및 이의 용도
CA2998753A1 (en) 2015-09-18 2017-03-23 St. Jude Children's Research Hospital Methods and compositions of inhibiting dcn1-ubc12 interaction
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (en) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome p450 modulators
WO2018118626A1 (en) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis
IL269068B (en) 2017-03-15 2022-09-01 Metacrine Inc Paranoid x receptor agonists and uses thereof
AU2018236275B2 (en) 2017-03-15 2022-05-12 Eli Lilly And Company Farnesoid X receptor agonists and uses thereof
US11135211B2 (en) 2017-04-28 2021-10-05 Acadia Pharmaceuticals Inc. Pimavanserin for treating impulse control disorder
EP3675827A1 (en) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations of pimavanserin
US11084817B2 (en) 2018-09-18 2021-08-10 Metacrine, Inc. Farnesoid X receptor agonists and uses thereof
WO2020257790A1 (en) 2019-06-20 2020-12-24 University Of Kentucky Research Foundation Pharmaceutically active pyrazolo-pyridone modulators of dcn1/2-mediated cullin neddylation
CN120938937A (zh) 2020-03-18 2025-11-14 伊莱利利公司 法尼醇x受体激动剂的制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2285A1 (fr) * 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
AU9740998A (en) * 1997-09-08 1999-03-29 F. Hoffmann-La Roche Ag Piperidine derivatives against malaria
CA2397981C (en) * 2000-03-06 2010-12-21 Acadia Pharmaceuticals, Inc. Azacyclic compounds for use in the treatment of serotonin related diseases
CA2406652A1 (en) * 2000-04-20 2001-11-01 Nps Allelix Corp. Aminopiperidines for use as glyt-1 inhibitors

Also Published As

Publication number Publication date
BR0113989A (pt) 2004-01-27
KR20030029978A (ko) 2003-04-16
AU2001291830A1 (en) 2002-04-02
CA2423315A1 (en) 2002-03-28
JP2004509866A (ja) 2004-04-02
ZA200302290B (en) 2004-06-30
US20040102431A1 (en) 2004-05-27
NO20031331D0 (no) 2003-03-24
NO20031331L (no) 2003-03-24
IL154363A0 (en) 2003-09-17
CN1458923A (zh) 2003-11-26
WO2002024649A1 (en) 2002-03-28
HUP0303360A2 (hu) 2004-01-28

Similar Documents

Publication Publication Date Title
MXPA03001982A (es) Amino-aza-cicloalcanos sustituidos utiles contra la malaria.
SE0101675D0 (sv) Novel composition
EA200100972A1 (ru) Новые соединения и композиции как ингибиторы протеаз
GEP20074133B (en) New process for the synthesis and new crystalline form of agomelatine and pharmaceutical compositions containing it
AU3652102A (en) Compounds and their uses
TW200510407A (en) Novel pyrrolodihydroisoquinolines as PDE 10 inhibitors
DE60112330D1 (en) Pyrazolopyridinderivate
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
MXPA03010158A (es) Sulfonamidas.
MXPA04006266A (es) Pirimidotriazinas como inhibidores de fosfatasa.
SE9901077D0 (sv) Novel use
MXPA04002282A (es) Nuevos compuestos y preparaciones como inhibidores de la catepsina.
WO2002038534A3 (en) Substituted alkyldiamines as inhibitors of plasmepsin or related proteases
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
MXPA05013012A (es) Formulaciones blanqueadoras fluorescentes estables al almacenamiento.
DE60201074D1 (en) Pyrazolopyridinderivate
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
TW200624429A (en) Novel cysteine protease inhibitors
MXPA03010259A (es) Nuevos derivados de 5-tio-ss-d-xilopiranosida, procedimiento de preparacion, composiciones farmaceuticas que los contienen y el uso terapeutico de los mismos.
MXPA05006587A (es) Compuestos de tiazol como derivados de antagonistas del receptor de la integrina.
HUP0401895A2 (hu) Paroxetin N-formil származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
MX2008007195A (es) Inhibidores de proteasas de cisteina, composiciones farmaceuticas de las mismas y sus aplicaciones terapeuticas.
TW200738689A (en) Salts and polymorphs of a VEGF-R inhibitor
WO2003097593A3 (en) Protease inhibitors
WO2002010124A3 (en) Salt forms of an hiv protease inhibitor